The Value of "More" Information: The Emerging Role of Novel Diagnostic Investigations in Cardiovascular Medicine

Research output: Contribution to journalArticle

Abstract

Evolution of diagnostic testing modalities in cardiovascular medicine has been rapid. Technological advances in cardiac imaging have enabled the assessment of cardiac texture and function with unprecedented resolution, while the assessment of coronary artery disease by non-invasive means has matured to rival coronary angiography. Similarly, developments in the area of serum biomarkers have given further insights into the risk experienced by patients with coronary artery disease, acute coronary syndromes and heart failure. However, the rate of this innovation calls for a moment's pause to refocus on the goals of the diagnostic and risk refinement process that is to deliver better care and improve clinical outcome. To date many studies in this area have fallen short of demonstrating such benefits and it is our responsibility as a clinical community to demand more of such innovation.

LanguageEnglish
Pages114-117
Number of pages4
JournalHeart Lung and Circulation
Volume18
Issue number2
DOIs
Publication statusPublished - Apr 2009

Keywords

  • Cardiac imaging
  • Comparative effectiveness

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{e6b04b1e3714403fb89f40de074b04d7,
title = "The Value of {"}More{"} Information: The Emerging Role of Novel Diagnostic Investigations in Cardiovascular Medicine",
abstract = "Evolution of diagnostic testing modalities in cardiovascular medicine has been rapid. Technological advances in cardiac imaging have enabled the assessment of cardiac texture and function with unprecedented resolution, while the assessment of coronary artery disease by non-invasive means has matured to rival coronary angiography. Similarly, developments in the area of serum biomarkers have given further insights into the risk experienced by patients with coronary artery disease, acute coronary syndromes and heart failure. However, the rate of this innovation calls for a moment's pause to refocus on the goals of the diagnostic and risk refinement process that is to deliver better care and improve clinical outcome. To date many studies in this area have fallen short of demonstrating such benefits and it is our responsibility as a clinical community to demand more of such innovation.",
keywords = "Cardiac imaging, Comparative effectiveness",
author = "Chew, {Derek P.} and Carolyn Astley",
year = "2009",
month = "4",
doi = "10.1016/j.hlc.2008.11.005",
language = "English",
volume = "18",
pages = "114--117",
journal = "Heart, lung & circulation",
issn = "1443-9506",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The Value of "More" Information

T2 - Heart, lung & circulation

AU - Chew, Derek P.

AU - Astley, Carolyn

PY - 2009/4

Y1 - 2009/4

N2 - Evolution of diagnostic testing modalities in cardiovascular medicine has been rapid. Technological advances in cardiac imaging have enabled the assessment of cardiac texture and function with unprecedented resolution, while the assessment of coronary artery disease by non-invasive means has matured to rival coronary angiography. Similarly, developments in the area of serum biomarkers have given further insights into the risk experienced by patients with coronary artery disease, acute coronary syndromes and heart failure. However, the rate of this innovation calls for a moment's pause to refocus on the goals of the diagnostic and risk refinement process that is to deliver better care and improve clinical outcome. To date many studies in this area have fallen short of demonstrating such benefits and it is our responsibility as a clinical community to demand more of such innovation.

AB - Evolution of diagnostic testing modalities in cardiovascular medicine has been rapid. Technological advances in cardiac imaging have enabled the assessment of cardiac texture and function with unprecedented resolution, while the assessment of coronary artery disease by non-invasive means has matured to rival coronary angiography. Similarly, developments in the area of serum biomarkers have given further insights into the risk experienced by patients with coronary artery disease, acute coronary syndromes and heart failure. However, the rate of this innovation calls for a moment's pause to refocus on the goals of the diagnostic and risk refinement process that is to deliver better care and improve clinical outcome. To date many studies in this area have fallen short of demonstrating such benefits and it is our responsibility as a clinical community to demand more of such innovation.

KW - Cardiac imaging

KW - Comparative effectiveness

UR - http://www.scopus.com/inward/record.url?scp=63549151429&partnerID=8YFLogxK

U2 - 10.1016/j.hlc.2008.11.005

DO - 10.1016/j.hlc.2008.11.005

M3 - Article

VL - 18

SP - 114

EP - 117

JO - Heart, lung & circulation

JF - Heart, lung & circulation

SN - 1443-9506

IS - 2

ER -